Grifols, ES0171996087

Grifols stock reports stronger first half with profit up 28.7%

Published on 10/07/2026 at 13:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Grifols stock reported EUR 227 million in first-half profit on July 28, 2026, up 28.7 percent year over year. The EUR 9.66 close trails the EUR 14.76 consensus target.

Aquarellbild von Barcelona mit Hafen, Bergen und mediterranem Licht — Aquarellmalerei zeigt die Küstenstadt Barcelona als Sitz von Grifols S.A. ES0171996087 in weichen, warmen Farbtönen, Illustration mit AI erstellt.

Grifols stock closed at EUR 9.66 on the BME on October 6, 2026, while the company reported a 28.7 percent increase in first-half net profit to EUR 227 million. The results published by Grifols on July 28, 2026, give the stock a stronger earnings backdrop despite continuing execution risks.

Profit growth strengthens the case

First-half revenue reached EUR 3.574 billion, rising 2.6 percent at constant currency, according to Grifols. Biopharma revenue grew 5.4 percent, making the division the main operating growth driver during the period.

The earnings improvement was also visible in cash generation. Yahoo Finance reported that adjusted EBITDA reached EUR 854 million in the first half, up 2.4 percent year over year at constant currency, with an adjusted EBITDA margin of 23.9 percent. Free cash flow before mergers and acquisitions was EUR 91 million, an improvement of EUR 103 million from the first half of 2025.

Immunoglobulins lead the portfolio

The operating mix is important because Biopharma expanded faster than group revenue. Immunoglobulin sales grew 12.8 percent at constant currency in the first half, while the company said Albumin performance in China faced pricing pressure.

Management is targeting an adjusted EBITDA margin of at least 25 percent for full-year 2026. The first-half margin of 23.9 percent leaves execution in the second half as the key test, particularly as Grifols works to stabilize Albumin and expand plasma sourcing outside the United States.

Consensus target stays above the stock

MarketScreener lists an OUTPERFORM mean consensus from 12 analysts and an average target price of EUR 14.76. Against the EUR 9.66 BME close on October 6, 2026, the stock lies 34.6 percent below that average target.

The broader rating picture is less uniform. MarketBeat reported on September 19, 2026, that Wall Street Zen upgraded Grifols from Hold to Buy, while its broader panel showed a Reduce consensus and an average target of USD 10.00 for the Nasdaq ADR.

Grifols stock trades below consensus

Grifols has a market capitalization of EUR 5.7 billion as of October 6, 2026. The combination of EUR 227 million in first-half profit, 12.8 percent immunoglobulin growth and a 23.9 percent adjusted EBITDA margin makes delivery against the 25 percent full-year margin goal the central valuation checkpoint.